Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 9/20 | 0.45 |
| ▸ | KLK7 | P49862 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | ADAM10 | O14672 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP3 | P08254 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22730621 | 1.00 | FKBP1A (0.45) | FKBP1AKLK7CTSLADAM10MMP2 | |
| SCHEMBL18084468 | 0.90 | KLK7 (0.47) | FKBP1AKLK7CTSL | |
| SCHEMBL934333 | 0.90 | KLK7 (0.47) | FKBP1AKLK7CTSL | |
| Hydrochloric Acid SCHEMBL26098360 | 0.89 | KLK7 (0.46) | FKBP1AKLK7CTSL | |
| Hydrochloric Acid SCHEMBL26098363 | 0.89 | KLK7 (0.46) | FKBP1AKLK7CTSL | |
| SCHEMBL16584597 | 0.88 | FKBP1A (0.46) | FKBP1AKLK7CTSL | |
| SCHEMBL31614218 | 0.88 | FKBP1A (0.46) | FKBP1AKLK7CTSL | |
| SCHEMBL16584596 | 0.88 | FKBP1A (0.46) | FKBP1AKLK7CTSL | |
| SCHEMBL20642435 | 0.87 | FKBP1A (0.45) | FKBP1AKLK7CTSL | |
| SCHEMBL21441839 | 0.87 | FKBP1A (0.45) | FKBP1AKLK7CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4605386-A1 | ANTI-VIRAL COMPOUNDS | Aligos Therapeutics, Inc. (US) | 2025-08-27 | — | — | EP | disclosed |
| US-20250059171-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-02-20 | — | — | US | disclosed |
| EP-4444711-A1 | ANTIVIRAL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2024-10-16 | — | — | EP | disclosed |
| US-20240182444-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2024-06-06 | — | — | US | disclosed |
| WO-2024086111-A1 | ANTI-VIRAL COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2024-04-25 | — | — | WO | disclosed |
| WO-2023104882-A1 | ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-06-15 | — | — | WO | disclosed |
| CN-112047939-B | Tetrahydropyridopyrimidine compound with anti-tumor activity | 江苏先声药业有限公司 | 2023-05-02 | — | — | CN | disclosed |
| US-11078202-B2 | β-lactamase inhibitor and use thereof | Suzhou Sinovent Pharmaceuticals Co., Ltd. (CN) | 2021-08-03 | — | — | US | disclosed |
| US-20210046057-A1 | Beta-lactamase inhibitor and use thereof | Suzhou Sinovent Pharmaceuticals Co., Ltd. (CN) | 2021-02-18 | — | — | US | disclosed |
| US-20210032260-A1 | Beta-lactamase inhibitor and use thereof | Evopoint Biosciences Co., Ltd. (CN) | 2021-02-04 | — | — | US | disclosed |
| EP-3744722-A1 | ß-LACTAMASE INHIBITOR AND USE THEREOF | Suzhou Sinovent Pharmaceuticals Co., Ltd. (CN) | 2020-12-02 | — | — | EP | disclosed |
| WO-2019144912-A1 | β-LACTAMASE INHIBITOR AND USE THEREOF | 苏州信诺维医药科技有限公司 | 2019-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210032260-A1 | Beta-lactamase inhibitor and use thereof | CYP51A1, LCT, CEL | FKBP1A 1678/4885KLK7 1159/4885CTSL 260/4885 |
| US-11078202-B2 | β-lactamase inhibitor and use thereof | CYP51A1, LCT, CEL | FKBP1A 1610/4885KLK7 1160/4885CTSL 249/4885 |
| US-20240182444-A1 | ANTI-VIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, HAVCR2 | FKBP1A 1766/4885KLK7 3296/4885CTSL 1088/4885 |
| US-20210046057-A1 | Beta-lactamase inhibitor and use thereof | CYP51A1, LCT, CEL | FKBP1A 1678/4885KLK7 1159/4885CTSL 260/4885 |
| US-20250059171-A1 | ANTIVIRAL COMPOUNDS | ZC3HAV1, ACE, EIF2AK2 | FKBP1A 586/4885KLK7 818/4885CTSL 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.